GET DAILY SIGNALSNeuroPace (NPCE) Q3 2026 Earnings Preview: Tracking RNS Momentum and IGE Progress
Key Takeaways
- NeuroPace, Inc. (NPCE) is scheduled to report third-quarter 2026 results after the market close on Thursday, November 12, 2026.
- Analysts expect a narrower loss of roughly $0.09 per share on revenue near $27.1 million, according to available consensus data.
- The RNS (responsive neurostimulation) System remains the core growth driver, with management guiding to 21%–23% full-year RNS revenue growth.
- Investors will closely watch updates on the idiopathic generalized epilepsy (IGE) regulatory pathway and full-year 2026 guidance.
- The company has beaten consensus EPS estimates in seven of its last eight quarters, raising the bar for continued execution.
Why This Report Carries Extra Weight
NeuroPace’s third-quarter 2026 update comes at a key moment in the company’s commercial path. Recent quarters have shown accelerating RNS System sales, growing numbers of active prescribers, and a stronger patient pipeline, alongside steady progress toward profitability. The company has already raised its full-year revenue outlook twice in 2026, which points to improved visibility on demand. At the same time, NeuroPace is working toward a potential FDA expansion into IGE, a much larger patient group. This quarter should give investors a clearer sense of whether the growth story holds up into 2027.
What the Consensus Is Pointing To
Consensus estimates for the third quarter of 2026 call for a loss of about $0.09 per share on revenue of roughly $27.1 million. A year earlier, the company posted a loss of $0.11 per share on $27.35 million in revenue, so analysts appear to be looking for modest margin gains even with a slightly softer top-line comparison. Revenue figures are also affected by the wind-down of the DIXI Medical business, now treated as discontinued operations.
RNS System revenue will be the figure to focus on most. Management has guided to 21%–23% full-year RNS growth and recently tightened total revenue guidance to $99.5–$101.5 million. Adjusted gross margin is expected in the 82%–83% range, while adjusted operating expenses and adjusted EBITDA (targeting a full-year loss of $7.5–$8.5 million) will also draw attention.
Investor Sentiment and Potential Market Reaction
Sentiment ahead of the report is generally constructive yet cautious. NPCE shares have moved sharply at times in 2026, and the stock’s reaction has often hinged on how results stack up against estimates and any shifts in full-year guidance. Having beaten EPS estimates in seven of the past eight quarters, the company has set a high bar for execution. Key risks include the timing of any FDA decision on the IGE expansion, possible margin pressure from material costs, and any slowdown in procedure volumes. A guidance update on RNS growth or the IGE timeline could matter more to the stock than the headline numbers alone.
Key Factors to Watch Beyond the Print
Looking ahead, the most significant catalyst remains the effort to expand the RNS System’s label into IGE. Management continues to expect a midyear FDA decision on the NAUTILUS PMA supplement, supported by the device’s breakthrough designation. Approval would meaningfully widen the addressable market.
Commercial metrics such as active prescribers, accounts, and the patient pipeline will also be important, as these have served as leading indicators of future demand. Longer-term initiatives, including the ECoG Assistant platform and a multimodal foundational AI model built on more than 27 million intracranial EEG recordings, represent additional growth avenues worth following. On the balance sheet, NeuroPace ended the second quarter with roughly $51.7 million in cash, equivalents, and short-term investments, alongside long-term borrowings near $59 million. Cash burn and the path to sustained profitability will stay central for investors assessing the stock’s risk profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Enhancing Research with AI Tools
In my own work, I find Tickeron’s AI Screener helpful for quickly filtering stocks by technical patterns, fundamentals, and AI-driven signals. It lets me scan efficiently and cross-check ideas against industry peers without spending hours on manual review, which keeps my process more focused when preparing for events like earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NPCE's Stochastic Oscillator entering oversold zone
The Stochastic Oscillator for NPCE moved into oversold territory on November 02, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NPCE's RSI Indicator exited the oversold zone, 21 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for NPCE just turned positive on October 20, 2026. Looking at past instances where NPCE's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +0.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where NPCE advanced for three days, in 236 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NPCE as a result. In 88 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NPCE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NPCE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NPCE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NPCE's P/B Ratio (35.644) is slightly higher than the industry average of (4.204). P/E Ratio (-21.649) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (4.427) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. NPCE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NPCE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement